Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
Article Abstract:
A combination of a protease inhibitor and two nucleoside analogs can significantly reduce blood levels of HIV in people infected with the virus. These are all drugs that are used to treat HIV infection. Ninety-seven HIV patients were randomly assigned to take the protease inhibitor indinavir alone, the nucleoside analogs zidovudine and lamivudine, or all three drugs. All the patients had 20,000 copies or more of HIV RNA per milliliter of blood. These levels were reduced to less than 500 copies in 90% of those taking all three drugs, compared to 43% of those taking indinavir and none of those taking the nucleoside analogs.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1997
User Contributions:
Comment about this article or add new information about this topic:
Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 infection (AIDS clinical trials group study A5095)
Article Abstract:
Metabolic changes are assessed after initiation of protease inhibitor (PI)-sparing regimes in antiretroviral-naive patients. The results have shown mild increases in glucose and decreases in insulin sensitivity in all regimens, whereas lipids are modestly higher in the 3-drug efavirenz (EFV)-containing arms and the metabolic dysfunctions of concern after the PI-sparing therapies are abnormal total cholesterol (TC) and lower high-density lipoprotein cholesterol (HDL-C) levels.
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2007
User Contributions:
Comment about this article or add new information about this topic:
Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection
Article Abstract:
A double-blind study, involving three antiretroviral regimens for the initial treatment of patients infected with HIV-1:zidovudine-lamivudine-abacavir, zidovudine-lamivudine plus efavirenz, and zidovudine-lamivudine-abacavir plus efavirenz, is presented.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: Results from ACTG 384
- Abstracts: Trends in management and outcomes of patients with acute myocardial infraction complicated by cardiogenic shock
- Abstracts: Watchful waiting vs repair of inguinal hernia in minimally symptomatic men: A randomized clinical trial. Effectiveness of Team-Managed Home-Based Primary Care: A Randomized Multicenter Trial